Wiki-CORONA

Search Results for: RIPK1

53 interactions involving RIPK1 - receptor interacting serine/threonine kinase 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
BIRC3 baculoviral IAP repeat containing 3
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIPK1-mediated regulated necrosis
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR2 non-canonical NF-kB pathway
  • Regulation of necroptotic cell death
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • Ub-specific processing proteases
  • IKK complex recruitment mediated by RIP1
CASP8 caspase 8
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Bardoxolone
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CCDC50 coiled-coil domain containing 50
CDC42BPB CDC42 binding protein kinase beta
CFLAR CASP8 and FADD like apoptosis regulator
  • TRAIL signaling
CRADD CASP2 and RIPK1 domain containing adaptor with death domain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
FADD Fas associated via death domain
  • Caspase activation via Death Receptors in the presence of ligand
  • TRIF-mediated programmed cell death
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
FAS Fas cell surface death receptor
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Hodgkin lymphoma
  • Esophageal cancer
  • Chronic lymphocytic leukemia (CLL)
  • Adult T-cell leukemia
GMPR guanosine monophosphate reductase
  • Purine salvage
  • Guanosine-5'-Monophosphate
H2BC13 H2B clustered histone 13
  • Recognition and association of DNA glycosylase with site containing an affected pyrimidine
  • Cleavage of the damaged pyrimidine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Cleavage of the damaged purine
  • Cleavage of the damaged purine
  • Meiotic synapsis
  • Packaging Of Telomere Ends
  • Pre-NOTCH Transcription and Translation
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • PRC2 methylates histones and DNA
  • Condensation of Prophase Chromosomes
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • HDACs deacetylate histones
  • HATs acetylate histones
  • HATs acetylate histones
  • SIRT1 negatively regulates rRNA expression
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • DNA methylation
  • Transcriptional regulation by small RNAs
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • G2/M DNA damage checkpoint
  • RNA Polymerase I Promoter Opening
  • RNA Polymerase I Promoter Escape
  • E3 ubiquitin ligases ubiquitinate target proteins
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Estrogen-dependent gene expression
  • Meiotic recombination
  • HCMV Early Events
  • HCMV Late Events
  • Transcriptional regulation of granulopoiesis
  • Amyloid fiber formation
HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Alvespimycin
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Mesalazine
  • Sulfasalazine
  • Acetylsalicylic acid
  • Auranofin
  • Arsenic trioxide
  • MLN0415
  • Acetylcysteine
IKBKE inhibitor of nuclear factor kappa B kinase subunit epsilon
  • SUMOylation of immune response proteins
  • TICAM1-dependent activation of IRF3/IRF7
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • Negative regulators of DDX58/IFIH1 signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • AGRO100
  • Tarenflurbil
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Incontinentia pigmenti
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
ITCH itchy E3 ubiquitin protein ligase
  • Downregulation of ERBB4 signaling
  • NOD1/2 Signaling Pathway
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Degradation of GLI1 by the proteasome
  • Hedgehog 'on' state
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Negative regulators of DDX58/IFIH1 signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
MAP3K1 mitogen-activated protein kinase kinase kinase 1
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • FCERI mediated MAPK activation
  • FCERI mediated MAPK activation
  • TRAF6 mediated NF-kB activation
  • TRAF6 mediated NF-kB activation
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
  • AZD-8330
MAP3K14 mitogen-activated protein kinase kinase kinase 14
  • CD28 dependent PI3K/Akt signaling
  • Dectin-1 mediated noncanonical NF-kB signaling
  • TNFR2 non-canonical NF-kB pathway
  • NIK - noncanonical NF-kB signaling
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
MAP3K3 mitogen-activated protein kinase kinase kinase 3
  • Interleukin-1 signaling
MAP3K8 mitogen-activated protein kinase kinase kinase 8
  • CD28 dependent PI3K/Akt signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
MTDH metadherin
NFKB1 nuclear factor kappa B subunit 1
  • Activation of NF-kappaB in B cells
  • RIP-mediated NFkB activation via ZBP1
  • Regulated proteolysis of p75NTR
  • Downstream TCR signaling
  • NF-kB is activated and signals survival
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated NF-kB activation
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • PKMTs methylate histone lysines
  • Transcriptional regulation of white adipocyte differentiation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Interleukin-1 processing
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • CD209 (DC-SIGN) signaling
  • CLEC7A/inflammasome pathway
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Neutrophil degranulation
  • The NLRP3 inflammasome
  • Transcriptional Regulation by VENTX
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • HCMV Early Events
  • Purinergic signaling in leishmaniasis infection
  • Acetylsalicylic acid
  • Thalidomide
  • Pranlukast
  • HE3286
  • P54
  • NOX-700
  • SGN-30
  • Custirsen
  • Andrographolide
  • Triflusal
NUMBL NUMB like endocytic adaptor protein
OTUD1 OTU deubiquitinase 1
PDXK pyridoxal kinase
  • Neutrophil degranulation
  • Vitamins B6 activation to pyridoxal phosphate
  • Pyridoxal
  • Pyridoxine
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL
  • (2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-ol
PELI1 pellino E3 ubiquitin protein ligase 1
  • Interleukin-1 signaling
  • IRAK1 recruits IKK complex
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
PRPF4B pre-mRNA processing factor 4B
PTK2 protein tyrosine kinase 2
  • Apoptotic cleavage of cellular proteins
  • Regulation of actin dynamics for phagocytic cup formation
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Signal regulatory protein family interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RAF/MAP kinase cascade
  • MET activates PTK2 signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • FCGR3A-mediated phagocytosis
  • 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE
  • 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE
PXDC1 PX domain containing 1
RIPK3 receptor interacting serine/threonine kinase 3
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • TRIF-mediated programmed cell death
  • TRP channels
  • RIPK1-mediated regulated necrosis
  • TLR3-mediated TICAM1-dependent programmed cell death
  • IKK complex recruitment mediated by RIP1
RNF11 ring finger protein 11
RNF216 ring finger protein 216
  • Negative regulators of DDX58/IFIH1 signaling
SQSTM1 sequestosome 1
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • Pink/Parkin Mediated Mitophagy
  • Interleukin-1 signaling
  • Pexophagy
  • Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
TAX1BP1 Tax1 binding protein 1
  • Regulation of TNFR1 signaling
  • Negative regulators of DDX58/IFIH1 signaling
TBK1 TANK binding kinase 1
  • IRF3 mediated activation of type 1 IFN
  • IRF3 mediated activation of type 1 IFN
  • Regulation of innate immune responses to cytosolic DNA
  • STAT6-mediated induction of chemokines
  • IRF3-mediated induction of type I IFN
  • Interleukin-37 signaling
  • TICAM1-dependent activation of IRF3/IRF7
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • Negative regulators of DDX58/IFIH1 signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
TICAM1 toll like receptor adaptor molecule 1
  • Caspase activation via Death Receptors in the presence of ligand
  • MyD88-independent TLR4 cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • TRIF-mediated programmed cell death
  • TICAM1 deficiency - HSE
  • TRAF3 deficiency - HSE
  • TLR3-mediated TICAM1-dependent programmed cell death
  • TICAM1-dependent activation of IRF3/IRF7
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • IKK complex recruitment mediated by RIP1
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
TNF tumor necrosis factor
  • Transcriptional regulation of white adipocyte differentiation
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR1-mediated ceramide production
  • TNFR2 non-canonical NF-kB pathway
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • TNF signaling
  • Etanercept
  • Adalimumab
  • Infliximab
  • Chloroquine
  • Epinephrine
  • Pseudoephedrine
  • Thalidomide
  • Glucosamine
  • Clenbuterol
  • Pranlukast
  • Amrinone
  • Isopropyl Alcohol
  • Afelimomab
  • YSIL6
  • SD118
  • PN0621
  • OMS-103HP
  • Talmapimod
  • VX-702
  • Apremilast
  • CRx-139
  • CYT007-TNFQb
  • Andrographolide
  • Ethyl pyruvate
  • AME-527
  • Dexanabinol
  • Golimumab
  • Certolizumab pegol
  • Pomalidomide
  • Binimetinib
  • Dilmapimod
  • Graft-versus-host disease
  • Asthma
  • Allograft rejection
  • Systemic lupus erythematosus
TNFAIP3 TNF alpha induced protein 3
  • NOD1/2 Signaling Pathway
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • Ovarian tumor domain proteases
  • Negative regulators of DDX58/IFIH1 signaling
TNFRSF10A TNF receptor superfamily member 10a
  • Caspase activation via Death Receptors in the presence of ligand
  • Cell surface interactions at the vascular wall
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Dimerization of procaspase-8
  • TRAIL signaling
TNFRSF10B TNF receptor superfamily member 10b
  • Caspase activation via Death Receptors in the presence of ligand
  • Cell surface interactions at the vascular wall
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Dimerization of procaspase-8
  • TRAIL signaling
  • HGS-TR2J
TNFRSF1A TNF receptor superfamily member 1A
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR1-mediated ceramide production
  • TNFs bind their physiological receptors
  • Interleukin-10 signaling
  • TNF signaling
  • 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
  • Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
TRADD TNFRSF1A associated via death domain
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • TNF signaling
TRAF1 TNF receptor associated factor 1
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
TRAF2 TNF receptor associated factor 2
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR2 non-canonical NF-kB pathway
  • Regulation of necroptotic cell death
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • Ub-specific processing proteases
  • Dimerization of procaspase-8
  • TNF signaling
  • TRAF6 mediated IRF7 activation
  • TRAF6 mediated NF-kB activation
  • TRAF6 mediated NF-kB activation
TRAF3 TNF receptor associated factor 3
  • TRAF3 deficiency - HSE
  • TNFR2 non-canonical NF-kB pathway
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • Ovarian tumor domain proteases
  • TICAM1-dependent activation of IRF3/IRF7
  • TRAF3-dependent IRF activation pathway
  • Negative regulators of DDX58/IFIH1 signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
TRAF5 TNF receptor associated factor 5
TRIM38 tripartite motif containing 38
  • Interferon gamma signaling
TRPC4AP transient receptor potential cation channel subfamily C member 4 associated protein
  • TRP channels
UBE2N ubiquitin conjugating enzyme E2 N
  • ISG15 antiviral mechanism
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • CLEC7A (Dectin-1) signaling
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • Formation of Incision Complex in GG-NER
  • G2/M DNA damage checkpoint
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Interleukin-1 signaling
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • Aggrephagy
  • Aggrephagy
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Antigen processing: Ubiquitination & Proteasome degradation
WRNIP1 WRN helicase interacting protein 1
YOD1 YOD1 deubiquitinase
  • Ovarian tumor domain proteases
ZFAND5 zinc finger AN1-type containing 5
ZNHIT1 zinc finger HIT-type containing 1